Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces that upon registration of the conditional capital of the Company today successfully completed the issuance of convertible bonds with a nominal amount of EUR 500,000. These convertible bonds constitute the first tranche of a total issuance of up to EUR 5m guaranteed by an agreement between YA Global Master SPV Ltd. (“YA Global”) and the Company. Following successful conversion or repayment of already issued tranches, the issuance of possible further tranches will be subject to future discretionary decisions by the Executive Board of the Company.
Excluding pre-emptive rights to existing shareholders, the convertible bonds will be issued to YA Global exclusively at a subscription price of 95% of the nominal amount. The bonds carry no interest, have a term until May 29, 2014 and are convertible into shares of Epigenomics immediately upon their issuance at the full discretion of the bearer of the bonds. The conversion price equals the average trading price of Epigenomics shares during a 5 day period prior to the time of conversion less a 5% discount, but cannot be lower than EUR 2.10.
Further details regarding the terms and conditions in connection with the issuance of convertible bonds according to the agreement with YA Global were announced by the ad hoc notification dated August 18, 2013.
– End of Ad hoc –
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Phone: +49 (0) 30 24345 386
Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.